The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy
Open accessAbstract
OBJECTIVE: To determine the incidence and prognostic significance of documented eradication of breast cancer axillary lymph node (ALN) metastases after neoadjuvant chemotherapy. SUMMARY BACKGROUND DATA: Neoadjuvant chemotherapy is the standard of care for patients with locally advanced breast cancer and is being evaluated in patients with earlier-stage operable disease. METHODS: One hundred ninety-one patients with locally advanced breast cancer and cytologically documented ALN metastases were treated in two prospective trials of doxorubicin-based neoadjuvant chemotherapy. Patients had breast surgery with level I and II axillary dissection followed by additional chemotherapy and radiation treatment. Nodal sections from 43 patients who were originally identified as having negative ALNs at surgery were reevaluated and histologically confirmed to be without metastases. An additional 1112 sections from these lymph node blocks were obtained; half were stained with an anticytokeratin antibody cocktail and analyzed. Survival was calculated using the Kaplan-Meier method. RESULTS: Of 191 patients with positive ALNs at diagnosis, 23% (43 patients) were converted to a negative axillary nodal status on histologic examination (median number of nodes removed = 16). Of the 43 patients with complete axillary conversion, 26% (n = 11) had N1 disease and 74% (n = 32) had N2 disease. On univariate analysis, patients with complete versus incomplete histologic axillary conversion were more likely to have initial estrogen-receptor-negative tumors, smaller primary tumors, and a complete pathologic response in the primary tumor. The 5-year disease-free survival rates were 87% in patients with preoperative eradication of axillary metastases and 51% for patients with residual nodal disease after neoadjuvant chemotherapy. Of the 39 patients with complete histologic conversion for whom nodal blocks were available, occult nodal metastases were found in additional nodal sections in 4 patients (10%). At a median follow-up of 61 months, the 5-year disease-free survival rates were 87% in patients without occult nodal metastases and 75% in patients with occult nodal metastases. CONCLUSIONS: Neoadjuvant chemotherapy can completely clear the axilla of microscopic disease before surgery, and occult metastases are found in only 10% of patients with a histologically negative axilla. The results of this study have implications for the potential use of sentinel lymph node biopsy as an alternative to axillary dissection in patients treated with neoadjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Beahrs, O. H., & Henson, D. E. (1992) · Medical Entomology and Zoology · Cited by 2,460
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Fisher, B., Redmond, C., Fisher, E. R., Bauer, M., Wolmark, N., Wickerham, D. L., Deutsch, M., Montague, E., Margolese, R., & Foster, R. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121102 · Cited by 1,376
Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy
Giuliano, A. E., Dale, P. S., Turner, R. R., Morton, D. L., Evans, S. W., & Krasne, D. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00016 · Cited by 930
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
Bonadonna, G., Valagussa, P., Brambilla, C., Ferrari, L., Moliterni, A., Terenziani, M., & Zambetti, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.93 · Cited by 566
Scholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y., Vilcoq, J. R., Durand, J. C., Dorval, T., Palangié, T., Jouve, M., Beuzeboc, P., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90537-1 · Cited by 424
Bacci, G., Picci, P., Ferrari, S., Ruggieri, P., Casadei, R., Tienghi, A., Prever, A. B. D., Gherlinzoni, F., Mercuri, M., & Monti, C. (1993) · Cancer · doi:10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c · Cited by 294
Cited by
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., Lebeau, A., Liedtke, C., Minckwitz, G. V., Nekljudova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70166-9 · Cited by 1,485
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., Sarkar, T. K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 782
Hennessy, B. T., Hortobagyi, G. N., Rouzier, R., Kuerer, H., Sneige, N., Buzdar, A. U., Kau, S. W., Fornage, B., Sahin, A., Broglio, K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5023 · Cited by 420
Self-citationGreen, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., Cristofanilli, M., Booser, D. J., Pusztai, L., Rivera, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.232 · Cited by 419
Self-citation
Metadata
- Authors
- Kuerer, H. M., Sahin, A. A., Hunt, K. K., Newman, L. A., Breslin, T. M., Ames, F. C., Ross, M. I., Buzdar, A. U., Hortobagyi, G. N., & Singletary, S. E.
- Venue
- Annals of Surgery
- Published
- 1999-07
- Volume
- 230
- Issue
- 1
- Pages
- 72
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W1985495442
- Cited by
- 357
- References
- 15
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy. https://app.cochat.ai/papers/10.1097/00000658-199907000-00011
- The paper
- Kuerer, H. M., Sahin, A. A., Hunt, K. K., Newman, L. A., Breslin, T. M., Ames, F. C., Ross, M. I., Buzdar, A. U., Hortobagyi, G. N., & Singletary, S. E. (1999). Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy. Annals of Surgery. https://doi.org/10.1097/00000658-199907000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.